Navigation Links
AMRI and Codexis Announce Technology Collaboration

ALBANY, N.Y. and REDWOOD CITY, Calif., Feb. 13, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) and Codexis (NASDAQ: CDXS) announced today that they have entered into a SMARTSOURCING™ partnership. The collaboration will provide opportunities to combine the two companies' capabilities and technologies for specific customer projects, yielding increased value to customers in the form of potentially lower costs, greater yields, cleaner processes and/or faster turnaround times.

(Logo: )

Under this non-exclusive, two-year agreement, the companies will align their respective strengths to identify and implement new and improved manufacturing routes for selected Active Pharmaceutical Ingredients (APIs). Combining Codexis' directed evolution technology that enables rapid enzyme discovery and optimization with AMRI's process development and manufacturing capabilities, including utilizing AMRI's proprietary microbial strains, creates synergies that will broaden both companies' ability to offer customers cost-effective, efficient, and sustainable manufacturing processes.

"We are pleased to announce this partnership with Codexis, a company that shares our philosophy of prioritizing scientific problem solving, innovation and customer service," said AMRI's Chairman, President and CEO, Thomas E. D'Ambra, Ph.D. "Combining AMRI's expertise in chemistry, biocatalysis, quality assurance and manufacturing with Codexis' cutting-edge biocatalysis technology and services, creates a proprietary advantage to our customer's development projects. This is another example of the AMRI SMARTSOURCING™ strategy of creating partnerships to deliver better outcomes to our customers."

"Codexis selected AMRI for this collaboration because AMRI understands the opportunity to  use biocatalysis for effective and comprehensive route assessment and manufacturing," says Dr. Peter Seufer-Wasserthal, SVP Pharmaceuticals, Codexis Inc. "Both companies have established strong reputations in the pharmaceutical manufacturing industry. By working together, AMRI and Codexis should identify more opportunities, which will benefit both companies and their customers by developing innovative, cost-effective and practical chemical processes."

About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).

About Codexis Inc.
Codexis, Inc. is a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals. Codexis' product lines include CodeXyme™ cellulase enzymes and CodeXol™ detergent alcohol. Partners and customers include global leaders such as Merck, Pfizer and Arch Pharmalabs. For more information, see

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Interim Chief Executive Officer to Present at Jefferies Conference
2. Codexis to Present at the Pacific Crest and Jefferies Conferences
3. Codexis Names Wes Bolsen VP and Chief Marketing Officer
4. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
5. AMRI Announces Fourth Quarter 2012 Adjusted EPS of $0.17
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Quantum Materials Corporation Announces Non-Heavy Metal (Cadmium-Free) Tetrapod Quantum Dots
8. The In View Series Announces Plans for a New Series on 3D-Printing
9. Qualitas Health and Valicor Renewables Announce Strategic Partnership to Commercialize Algae-Based Omega-3 Supplements
10. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
11. The In View series hosted by Larry King Announces plans for a series on Autoimmune Diseases
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):